Answers are grounded in this paper and cite their sources.
Microtubule (MT) acetylation is frequently elevated in cancer and associated with poor prognosis. Alpha-tubulin acetyltransferase 1 (ATAT1), the principal enzyme responsible for this modification, has therefore emerged as a potential therapeutic target. However, which cancer types depend on ATAT1 activity and are selectively vulnerable to its inhibition remains unclear. Here, using a phospho-specific marker of ATAT1 activity, we identify pancreatic ductal adenocarcinoma (PDAC) as an ATAT1-dependent malignancy. ATAT1 activity is elevated in human PDAC and genetically engineered mouse models, emerging during pancreatic intraepithelial neoplasia and persisting in a substantial subset of tumors. Genetic inactivation or pharmacologic inhibition of ATAT1 suppresses PDAC cell growth, reduces orthotopic tumor burden, and markedly inhibits tumor initiation in KPC mice without overt toxicity. Mechanistically, ATAT1-dependent MT acetylation sustains Akt signaling, resulting in inhibitory phosphorylation of GSK3β and stabilization of the DNA methyltransferase DNA methyltransferase 1 (DNMT1). Elevated DNMT1 promotes repression of tumor suppressor genes, including NDRG4, whereas inhibition of ATAT1 or DNMT1 restores NDRG4 expression and impairs tumor growth. Together, these findings identify a previously unrecognized ATAT1-Akt-GSK3β-DNMT1 signaling axis linking cytoskeletal acetylation to NDRG4 repression and reveal ATAT1 as a therapeutic vulnerability during the early stages of pancreatic tumorigenesis.
No takes yet. Share an insight, caveat, or question.
Podgorski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: